Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX, Wang H, Liu C, Kovats S, Velazquez R, Lu H, Pant B, Shirley M, Meyer MJ, Pu M, Lim J, Fleming M, Alexander L, Farsidjani A, LaMarche MJ, Moody S, Silver SJ, Caponigro G, Stuart DD, Abrams TJ, Hammerman PS, Williams J, Engelman JA, Goldoni S, Mohseni M. Hao HX, et al. Among authors: shirley m. Mol Cancer Ther. 2019 Dec;18(12):2368-2380. doi: 10.1158/1535-7163.MCT-19-0170. Epub 2019 Aug 22. Mol Cancer Ther. 2019. PMID: 31439712
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.
Leung GP, Feng T, Sigoillot FD, Geyer FC, Shirley MD, Ruddy DA, Rakiec DP, Freeman AK, Engelman JA, Jaskelioff M, Stuart DD. Leung GP, et al. Among authors: shirley md. Mol Cancer Res. 2019 Jan;17(1):199-211. doi: 10.1158/1541-7786.MCR-18-0327. Epub 2018 Sep 10. Mol Cancer Res. 2019. PMID: 30201825
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ, Mulford IJ, Sharp F, Liang J, Kurtulus S, Trabucco G, Quinn DS, Longmire TA, Patel N, Patil R, Shirley MD, Chen Y, Wang H, Ruddy DA, Fabre C, Williams JA, Hammerman PS, Mataraza J, Platzer B, Halilovic E. Wang HQ, et al. Cancer Res. 2021 Jun 1;81(11):3079-3091. doi: 10.1158/0008-5472.CAN-20-0189. Epub 2021 Jan 27. Cancer Res. 2021. PMID: 33504557
The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma.
Rago F, Elliott G, Li A, Sprouffske K, Kerr G, Desplat A, Abramowski D, Chen JT, Farsidjani A, Xiang KX, Bushold G, Feng Y, Shirley MD, Bric A, Vattay A, Möbitz H, Nakajima K, Adair CD, Mathieu S, Ntaganda R, Smith T, Papillon JPN, Kauffmann A, Ruddy DA, Bhang HC, Castelletti D, Jagani Z. Rago F, et al. Mol Cancer Ther. 2020 Oct;19(10):2186-2195. doi: 10.1158/1535-7163.MCT-19-1013. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747420
CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.
Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, DeWeck A, Abramowski D, Wan J, Shirley MD, Neshat SY, Rakiec D, de Beaumont R, Weber O, Kauffmann A, McDonald ER 3rd, Keen N, Hofmann F, Sellers WR, Schmelzle T, Stegmeier F, Schlabach MR. Munoz DM, et al. Among authors: shirley md. Cancer Discov. 2016 Aug;6(8):900-13. doi: 10.1158/2159-8290.CD-16-0178. Epub 2016 Jun 3. Cancer Discov. 2016. PMID: 27260157
Dacomitinib: First Global Approval.
Shirley M. Shirley M. Drugs. 2018 Dec;78(18):1947-1953. doi: 10.1007/s40265-018-1028-x. Drugs. 2018. PMID: 30506139 Review.
Sebelipase alfa: first global approval.
Shirley M. Shirley M. Drugs. 2015 Nov;75(16):1935-40. doi: 10.1007/s40265-015-0479-6. Drugs. 2015. PMID: 26452566 Review.
Olaratumab: First Global Approval.
Shirley M. Shirley M. Drugs. 2017 Jan;77(1):107-112. doi: 10.1007/s40265-016-0680-2. Drugs. 2017. PMID: 27995580 Review.
348 results